KYORIN Pharmaceutical Co., Ltd. Overview
Pro stress-test →KYORIN Pharmaceutical manufactures pharmaceuticals and medical products, producing and distributing prescription medicines, quasi-drugs, diagnostic drugs, medical tools, medical equipment, health foods, cosmetics, and other products. Through its subsidiaries, the company researches, develops, manufactures, and sells ethical and generic drugs in Japan and internationally.
Strategic Profile
Pro stress-test →The company offers a portfolio of specialty therapeutics including Flutiform (asthma), Pentasa (ulcerative colitis/Crohn's disease), and Nasonex (allergic rhinitis), alongside diagnostics and contract manufacturing services. KYORIN has development and commercialization agreements with innovators like Hyfe Inc. for digital therapeutics focused on chronic cough.
Competitive Landscape
Pro stress-test →KYORIN competes in Japan's fragmented pharmaceutical market against larger global players (Takeda, Daiichi Sankyo, Astellas) and generic manufacturers. The company's focus on specialty therapeutics and licensing partnerships provides differentiation, though scale disadvantages persist in competing for blockbuster drugs.
Industry Context
KYORIN Pharmaceutical Co., Ltd. operates in Pharmaceuticals & Biotech.
Key facts
Founded: 1923 · Headquarters: Tokyo, Japan · Employees: 2,000 · Revenue: Not available in search results · Market cap: ¥88.53B (~$600M USD equivalent)